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Background: Type 2 diabetes mellitus (T2DM) predisposes patients to opportunistic
infections, such as invasive candidiasis. Treatment of candidiasis is challenged by the
emerging resistance of Candida species. In this study, the antifungal drug resistance
patterns of Candida species present in the oral mucosa of T2DM Libyan patients was
investigated.
Methods: Seventy four (74) oral Candida isolates collected from T2DM patients in
Misrata, Libya were characterised using the VITEK 2 Compact system.
Results: Prevalent species included C. albicans, C. glabrata, C. dubliniensis, C. krusei, C.
tropicalis, C. sake, C. kefyr, C. guilliermondii, C. parapsilopsis, C. membranifaciens and
C. magnoliae.
Drug susceptibility showed an emerging resistance across representatives of all species for
which breakpoints were available, with the exception of C. parapsilopsis. Although there
are no established interpretative breakpoints for these species, three C. sake isolates and
the C. membranifaciens isolate also had high MIC values for fluconazole. The tested
isolates were found to be largely susceptible to caspofungin and micafungin. All C.
albicans isolates were susceptible to the echinocandins, amphotericin B and 5-flucytosine.
Resistance to more than one drug class was seen in C. dubliniensis, C. glabrata and C.
krusei isolates.
Conclusion: Although the susceptibility results for the echinocandins were encouraging,
resistance against the azoles was apparent and should not be ignored. This was especially
so in the case of fluconazole, which is often the only locally available antifungal drug for
the treatment of disseminated candidiasis.
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Figure 1: Sample collection, isolation, identification and drug susceptibility techniques used in this study.
T2DM patients are more vulnerable to fungal infection, particularly Candida infections of
the oral cavity1,2, due to increased salivary glucose3 and the heightened availability of
Candida receptors4,5 in these subjects, with colonization by potentially pathogenic
Candida strains being further enhanced by the hyposalivation associated with DM6.
Drug classes routinely used in the fight against Candida infections include the routinely
used triazoles (e.g. fluconazole and voriconazole), that affect ergosterol production in the
fungal cell membrane; the echinocandins (e.g. micafungin and caspofungin), that inhibit
β1-3 glucan synthesis in the fungal cell wall; 5-flucytosine, a fluorinated analogue
pyrimidine that inhibits DNA and protein synthesis and amphotericin B, a polyene
antifungal used for systemic infections that binds to ergosterol in the fungal cell
membrane.
There is an absence of published data on the prevalence of Candida infection in T2DM in
the Libyan population. This study aimed to investigate the prevalence and antifungal drug
resistance patterns of Candida species in T2DM Libyan patients.
Ethical clearance for this project was granted by the Ethics Committee at University of
Western Cape, South Africa and authorisation for sample collection was obtained from the
Ministry of Health in Libya. Samples from T2DM patients were collected by scraping the
oral mucosa and tongue with a sterile cotton swab, followed by culture on Sabouraud
dextrose agar and incubation at 37˚C for 24 hours.
Confirmation of Candida species was achieved using microscopy, Gram staining, and the
germ tube test, while Fluka chromogenic Candida identification agar (Cat. no. 94382;
Sigma-Aldrich, St. Louis, MI, USA) and Oxoid chromogenic Candida agar (Cat. no.
CM1002A; Oxoid, Hampshire, UK) and the API ID 32 C system (bioMérieux, Marcy
l'Etoile, France) were used for presumptive species identification. The susceptibility to 6
antifungal drugs (amphotericin B, caspofungin, micafungin, fluconazole, voriconazole and
flucytosine) was tested using the Vitek 2 Compact system (bioMérieux, Marcy l'Etoile,
France).
Nine Candida type strains were used as quality control organisms for the species
identification and antifungal drug susceptibility testing, namely C. albicans (ATCC 90028
and NCPF 3281), C. tropicalis (ATCC 950), C. dubliniensis (NCPF 3949a), C. glabrata
(ATCC 26512), C. krusei (ATCC 2159), C. parapsilosis (ATCC 22019), C. kefyr (ATCC
4135) and C. lusitaniae (ATCC 3449).
Eleven Candida species were identified and tested for their resistance to
antifungals. These included C. albicans (20 isolates), C. glabrata (22 isolates),
C. dubliniensis (13 isolates), C. krusei (5 isolates), C. tropicalis (4 isolates), C.
sake (4 isolates), C. kefyr (2 isolates), C. guilliermondii (1 isolate), C.






















Susceptible 20 19 13 4 4 2 1 1
Intermediate 0 0 0 0 0 0 0 0
Resistant 0 3 0 1 0 0 0 0
5-Flucytosine
Susceptible 20 22 12 0 4 2 1 1
Intermediate 0 0 0 0 0 0 0 0
Resistant 0 0 1 5 0 0 0 0
Caspofungin
Susceptible 20 0 13 5 4 1 1 1
Intermediate 0 22 0 0 0 1 0 0
Resistant 0 0 0 0 0 0 0 0
Micafungin
Susceptible 20 22 12 5 4 2 1 1
Intermediate 0 0 1 0 0 0 0 0
Resistant 0 0 0 0 0 0 0 0
Fluconazole
Susceptible 16 0 10 0 2 1 0 1
Intermediate 2 22 1 0 2 1 1 0
Resistant 2 0 2 5 0 0 0 0
Voriconazole
Susceptible 19 22 11 5 4 2 1 1
Intermediate 0 0 0 0 0 0 0 0
Resistant 1 0 2 1 0 0 0 0
Table 1: Candida species distribution and susceptibility results (only species for which interpretative 
breakpoints are available are shown)
The laboratory identification and antimicrobial susceptibility testing of Candida
infections is not commonly preformed in Libya, with patients being treated
according to their clinical symptoms.
The susceptibility of the majority of isolates to the different classes of antifungal
drugs is encouraging, especially in the case of the echinocandins. However, the
variety of Candida species seen in this population, including species that are
inherently resistant to fluconazole, is a novel finding, as is the resistance of all C.
krusei isolates to 5-flucytosine.
The monitoring of regional Candida species prevalence and drug susceptibility
in Libyan diabetic patients is imperative, as the empirical treatment of these
infections might be exacerbating the development of drug resistance.
Of the three rarer species for which no interpretative breakpoints have been
established, 3 C. sake isolates and the C. membranifaciens isolate showed high
MIC values when exposed to fluconazole (with MICs ranging between 4µg/ml
and 8µg/ml). All of these rarer species demonstrated low MIC values to the
other antifungal drugs.
